Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

N-propionyl-cysteaminylphenol-magnetite conjugate (NPrCAP/M) is a nanoparticle for the targeted growth suppression of melanoma cells.

Sato M, Yamashita T, Ohkura M, Osai Y, Sato A, Takada T, Matsusaka H, Ono I, Tamura Y, Sato N, Sasaki Y, Ito A, Honda H, Wakamatsu K, Ito S, Jimbow K.

J Invest Dermatol. 2009 Sep;129(9):2233-41. doi: 10.1038/jid.2009.39. Epub 2009 Mar 19.

2.

Growth inhibition of re-challenge B16 melanoma transplant by conjugates of melanogenesis substrate and magnetite nanoparticles as the basis for developing melanoma-targeted chemo-thermo-immunotherapy.

Takada T, Yamashita T, Sato M, Sato A, Ono I, Tamura Y, Sato N, Miyamoto A, Ito A, Honda H, Wakamatsu K, Ito S, Jimbow K.

J Biomed Biotechnol. 2009;2009:457936. doi: 10.1155/2009/457936. Epub 2009 Oct 8.

3.

Melanoma-targeted chemo-thermo-immuno (CTI)-therapy using N-propionyl-4-S-cysteaminylphenol-magnetite nanoparticles elicits CTL response via heat shock protein-peptide complex release.

Sato A, Tamura Y, Sato N, Yamashita T, Takada T, Sato M, Osai Y, Okura M, Ono I, Ito A, Honda H, Wakamatsu K, Ito S, Jimbow K.

Cancer Sci. 2010 Sep;101(9):1939-46. doi: 10.1111/j.1349-7006.2010.01623.x.

4.

Mechanism of putative neo-antigen formation from N-propionyl-4-S-cysteaminylphenol, a tyrosinase substrate, in melanoma models.

Ito S, Nishigaki A, Ishii-Osai Y, Ojika M, Wakamatsu K, Yamashita T, Tamura Y, Ito A, Honda H, Nakayama E, Jimbow K.

Biochem Pharmacol. 2012 Sep 1;84(5):646-53. doi: 10.1016/j.bcp.2012.06.015. Epub 2012 Jun 21.

PMID:
22728921
5.

N-propionyl-4-S-cysteaminylphenol induces apoptosis in B16F1 cells and mediates tumor-specific T-cell immune responses in a mouse melanoma model.

Ishii-Osai Y, Yamashita T, Tamura Y, Sato N, Ito A, Honda H, Wakamatsu K, Ito S, Nakayama E, Okura M, Jimbow K.

J Dermatol Sci. 2012 Jul;67(1):51-60. doi: 10.1016/j.jdermsci.2012.04.009. Epub 2012 May 2.

PMID:
22622238
6.

T-cell receptor repertoires of tumor-infiltrating lymphocytes after hyperthermia using functionalized magnetite nanoparticles.

Ito A, Yamaguchi M, Okamoto N, Sanematsu Y, Kawabe Y, Wakamatsu K, Ito S, Honda H, Kobayashi T, Nakayama E, Tamura Y, Okura M, Yamashita T, Jimbow K, Kamihira M.

Nanomedicine (Lond). 2013 Jun;8(6):891-902. doi: 10.2217/nnm.12.142. Epub 2012 Oct 15.

PMID:
23066648
7.

Melanoma-Targeted Chemothermotherapy and In Situ Peptide Immunotherapy through HSP Production by Using Melanogenesis Substrate, NPrCAP, and Magnetite Nanoparticles.

Jimbow K, Ishii-Osai Y, Ito S, Tamura Y, Ito A, Yoneta A, Kamiya T, Yamashita T, Honda H, Wakamatsu K, Murase K, Nohara S, Nakayama E, Hasegawa T, Yamamoto I, Kobayashi T.

J Skin Cancer. 2013;2013:742925. doi: 10.1155/2013/742925. Epub 2013 Feb 21.

8.

Selective incorporation and specific cytocidal effect as the cellular basis for the antimelanoma action of sulphur containing tyrosine analogs.

Thomas PD, Kishi H, Cao H, Ota M, Yamashita T, Singh S, Jimbow K.

J Invest Dermatol. 1999 Dec;113(6):928-34.

9.

4-S-Cysteaminylphenol-loaded magnetite cationic liposomes for combination therapy of hyperthermia with chemotherapy against malignant melanoma.

Ito A, Fujioka M, Yoshida T, Wakamatsu K, Ito S, Yamashita T, Jimbow K, Honda H.

Cancer Sci. 2007 Mar;98(3):424-30.

10.

Synthesis and antitumour effect of the melanogenesis-based antimelanoma agent N-propionyl-4-S-cysteaminylphenol.

Tandon M, Thomas PD, Shokravi M, Singh S, Samra S, Chang D, Jimbow K.

Biochem Pharmacol. 1998 Jun 15;55(12):2023-9.

PMID:
9714323
11.

Anticancer effect and immune induction by hyperthermia of malignant melanoma using magnetite cationic liposomes.

Suzuki M, Shinkai M, Honda H, Kobayashi T.

Melanoma Res. 2003 Apr;13(2):129-35.

PMID:
12690295
12.

Sulfur containing tyrosine analogs can cause selective melanocytotoxicity involving tyrosinase-mediated apoptosis.

Minamitsuji Y, Toyofuku K, Sugiyama S, Yamada K, Jimbow K.

J Investig Dermatol Symp Proc. 1999 Sep;4(2):130-6.

13.

A/C magnetic hyperthermia of melanoma mediated by iron(0)/iron oxide core/shell magnetic nanoparticles: a mouse study.

Balivada S, Rachakatla RS, Wang H, Samarakoon TN, Dani RK, Pyle M, Kroh FO, Walker B, Leaym X, Koper OB, Tamura M, Chikan V, Bossmann SH, Troyer DL.

BMC Cancer. 2010 Mar 30;10:119. doi: 10.1186/1471-2407-10-119.

15.
16.

Tumor regression by combined immunotherapy and hyperthermia using magnetic nanoparticles in an experimental subcutaneous murine melanoma.

Ito A, Tanaka K, Kondo K, Shinkai M, Honda H, Matsumoto K, Saida T, Kobayashi T.

Cancer Sci. 2003 Mar;94(3):308-13.

17.

Magnetite nanoparticle-loaded anti-HER2 immunoliposomes for combination of antibody therapy with hyperthermia.

Ito A, Kuga Y, Honda H, Kikkawa H, Horiuchi A, Watanabe Y, Kobayashi T.

Cancer Lett. 2004 Aug 30;212(2):167-75.

PMID:
15279897
18.

The in vivo antimelanoma effect of 4-S-cysteaminylphenol and its n-acetyl derivative.

Miura T, Jimbow K, Ito S.

Int J Cancer. 1990 Nov 15;46(5):931-4.

PMID:
2121652
19.

Characterization of intratumor magnetic nanoparticle distribution and heating in a rat model of metastatic spine disease.

Zadnik PL, Molina CA, Sarabia-Estrada R, Groves ML, Wabler M, Mihalic J, McCarthy EF, Gokaslan ZL, Ivkov R, Sciubba D.

J Neurosurg Spine. 2014 Jun;20(6):740-50. doi: 10.3171/2014.2.SPINE13142. Epub 2014 Apr 4.

PMID:
24702509
20.

Efficacy of acetaminophen in skin B16-F0 melanoma tumor-bearing C57BL/6 mice.

Vad NM, Kudugunti SK, Graber D, Bailey N, Srivenugopal K, Moridani MY.

Int J Oncol. 2009 Jul;35(1):193-204.

PMID:
19513568

Supplemental Content

Support Center